Abstract
Purpose :
To evaluate the repeatability of two test strategies offered for the Imovifa perimeter in healthy eyes and glaucomatous eyes.
Methods :
Subjects with glaucoma in at least one eye were recruited from an optometry practice, and normal subjects were recruited from employees and their families. Four tests were performed in a single visit, two with the AIZE-Rapid test strategy, and two with the AIZE strategy, in random order. Subjects were offered a rest between tests. Each test begins with a foveal test. The default test for Imovifa is binocular, with eyes being tested randomly throughout the process. To ensure patients had sufficient binocular vision to perform the default test, if the subject saw more than the intended four spots surrounding the center during the foveal test, the study eye was tested monocularly. Mean deviation (MD), and pattern standard deviation (PSD) were calculated for all tested eyes. Bland Altman analysis was performed and the repeatability standard deviation was calculated as the square root of the variance averaged across all pairs of measurements.
Results :
Nine subjects with glaucoma (age range: 46 to 88, mean 74, standard deviation: 16), and eleven without glaucoma (age range: 40 to 77, mean: 55, standard deviation: 13) were enrolled and tested. MD for the glaucoma subjects ranged from 0.55 to -21 dB, but most eyes had early glaucoma with an average MD of -3.4 dB and a standard deviation of 6.7 dB. Repeatability standard deviation was 1.2 dB for the MD for glaucoma eyes, and 0.2 dB for normal eyes. Repeatability standard deviation was 0.31 dB for the PSD for glaucoma eyes, and 0.05 dB for normal eyes. The figure shows an example of two repeated AIZE-Rapid tests for an eye with early glaucoma. The total time ranged from 1.8 to 3.4 minutes for normal eyes and 2.0 to 6.9 minutes for glaucoma eyes, which represented both eyes in all but two subjects.
Conclusions :
The Imovifa perimeter has acceptable repeatability for clinical use, with binocular test times that allow for rapid testing in a clinical setting. Repeatability is worse in eyes with glaucoma, as expected for visual field testing.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.